
NeuroCONCISE is a neurotechnology company that has developed a revolutionary wearable brain-computer interface platform combining patented FlexEEG hardware and AI-driven software. Their FlexEEG device is a slim, flexible, and unobtrusive EEG headset embedded in stylish headwear, enabling brainwave measurement and analysis for applications in neurofeedback, brain monitoring, medical research, gaming, and rehabilitation. The company offers a suite of software products including NeuroPRECISE for real-time data visualization, NeuroSHINE for clinical assessment and communication for immobile patients, NeuroREFLECT for neurotechnology training and rehabilitation, and EncephaloCloud for GDPR-compliant cloud data storage and analytics. NeuroCONCISE targets clinicians, patients, neurogamers, and researchers, with ongoing clinical trials focusing on brain injury assessment, stroke rehabilitation, and assistive communication. The company is built on over 17 years of award-winning AI research and collaborates with Ulster University and other research centers, positioning itself as an innovative leader in neurotechnology with potential to impact patient care and quality of life.

NeuroCONCISE is a neurotechnology company that has developed a revolutionary wearable brain-computer interface platform combining patented FlexEEG hardware and AI-driven software. Their FlexEEG device is a slim, flexible, and unobtrusive EEG headset embedded in stylish headwear, enabling brainwave measurement and analysis for applications in neurofeedback, brain monitoring, medical research, gaming, and rehabilitation. The company offers a suite of software products including NeuroPRECISE for real-time data visualization, NeuroSHINE for clinical assessment and communication for immobile patients, NeuroREFLECT for neurotechnology training and rehabilitation, and EncephaloCloud for GDPR-compliant cloud data storage and analytics. NeuroCONCISE targets clinicians, patients, neurogamers, and researchers, with ongoing clinical trials focusing on brain injury assessment, stroke rehabilitation, and assistive communication. The company is built on over 17 years of award-winning AI research and collaborates with Ulster University and other research centers, positioning itself as an innovative leader in neurotechnology with potential to impact patient care and quality of life.
Founded: 2016
Headquarters: Northern Ireland (Derry)
Core product: FlexEEG wearable EEG + AI software platform
Applications: Clinical assessment, rehabilitation, assistive communication, neurogaming, research
Founder & CEO: Professor Damien Coyle
Known investors: Techstart Ventures; Innovation Ulster; Pitch@Palace
Non-invasive brain monitoring and brain–computer interfaces for clinical assessment, rehabilitation, assistive communication, neurofeedback and neurogaming.
2016
Biotechnology
Most recent listed funding round per company profiles; multiple early-stage funding events and non-equity assistance reported.
“Techstart Ventures; Innovation Ulster; Pitch@Palace”